FINWIRES · TerminalLIVE
FINWIRES

HKG:9966

8 stories mentioning HKG:9966Updated 41d ago

Every FINWIRES story that references HKG:9966, newest first.

What's the latest news on HKG:9966?

Asia

Alphamab Oncology Licenses Cancer Drug Candidate to Pathos AI for Up to $2.09 Billion

Alphamab Oncology's (HKG:9966) wholly owned subsidiary, Jiangsu Alphamab Biopharmaceuticals, has granted Pathos AI an exclusive license to develop and commercialize cancer drug JSKN016 outside mainland China, Hong Kong, Macau and Taiwan, in a deal worth up to $2.09 billion.Under the agreement, Alphamab will receive a $125 million upfront payment and is eligible for additional milestone payments and tiered royalties based on sales in the licensed markets, according to a Hong Kong bourse filing.As part of the deal, Pathos AI granted Alphamab an option to invest up to $62.5 million in its preferred shares.

HKG:9966
Asia

CSPC Pharma Unit, Alphamab Oncology's Breast Cancer Drug Application Granted Priority Review in China

CSPC Pharmaceutical (HKG:1093) said a new drug application for Anbenitamab was accepted by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The application for Anbenitamab, co-developed by Shanghai JMT-Bio Technology, a unit of the company, and Alphamab Oncology (HKG:9966), has also been included in the priority review and approval procedures.The indication for the application is Anbenitamab in combination with docetaxel (albumin-bound) ± carboplatin as neoadjuvant therapy to treat breast cancer in adults.

HKG:1093HKG:9966
Asia

Alphamab Oncology Gets China Nod for Phase III Trial of Cervical Cancer Drug Candidate; Shares Climb 6%

Alphamab Oncology (HKG:9966) obtained approval to begin a phase III clinical study of JSKN033 from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.Shares of the company were up nearly 6% in Tuesday afternoon trading.The drug will be tested as monotherapy in patients with recurrent or metastatic cervical cancer.

HKG:9966
Asia

Alphamab Says Phase 3 Study of Breast Cancer Drug Meets Primary Endpoint

Alphamab Oncology (HKG:9966) said a Phase 3 study of Anbenitamab, or KN026, which it co-developed with Shanghai JMT-Bio Technology, a subsidiary of CSPC Pharma (HKG:1093), met its primary endpoint in the first-line treatment of HER2-positive advanced breast cancer, according to a Wednesday bourse filing.The company said KN026, in combination with albumin-bound docetaxel HB1801, significantly improved progression-free survival and reduced the risk of disease progression or death compared with the current standard regimen of trastuzumab, pertuzumab, and docetaxel.The study enrolled about 880 patients and compared KN026 plus HB1801 against the standard treatment regimen in patients with HER2-positive advanced breast cancer.

HKG:1093HKG:9966
Asia

Alphamab Oncology CEO Buys Shares

Alphamab Oncology (HKG:9966) said its controlling shareholder and CEO Xu Ting bought 554,000 shares of the company from the open market on Thursday, according to a Friday filing with the Hong Kong bourse.The purchases were on top of the 122,000 shares bought by certain members of the company's management, also on the same day.The shares were purchased for HK$7.375 on average, or nearly HK$5 million in total.Xu now holds 314.28 million shares, representing 32.4% of the business, the firm said.

HKG:9966
Asia

3D Medicines Completes Enrollment Early in Lung Cancer Trial

3D Medicines (HKG:1244) said enrollment was completed ahead of schedule in a phase 3 clinical trial of Envafolimab for the neoadjuvant and adjuvant treatment of non-small cell lung cancer, according to a Thursday Hong Kong bourse filing.Shares of the cancer therapy developer gained over 1% in late-morning trade on Friday.The randomized, double-blind, multi-center study is evaluating Envafolimab combined with platinum-based chemotherapy in patients with resectable stage 3 non-small cell lung cancer.The trial, co-developed with Alphamab Oncology (HKG:9966), enrolled about 390 patients across around 60 clinical research centers in China.

HKG:1244HKG:9966
Asia

Alphamab Oncology Doses First Patient in Phase 2 Study of JSKN033

Alphamab Oncology (HKG:9966) dosed the first patient in the phase 2 clinical study of JSKN033, according to a Wednesday filing with the Hong Kong bourse.The firm plans to study the medicine as a first-line treatment of advanced cervical cancer.

HKG:9966
Asia

Alphamab Oncology Swings to Loss in 2025

Alphamab Oncology (HKG:9966) logged 113.9 million yuan in attributable loss for 2025, swinging from a profit of 166.3 million yuan a year earlier, according to a Hong Kong bourse filing Tuesday.The cancer therapy developer's shares fell by more than 3% in late-morning trade on Wednesday.Loss per share was 0.12 yuan, compared with earnings of 0.17 yuan in the prior year.Revenue fell to 566.2 million yuan from 640.1 million yuan in 2024, figures showed.

HKG:9966

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:9966 in your portfolio
WheelAI
WheelAI
Analyze HKG:9966 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:9966